Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab

Journal of Clinical Gastroenterology

Volumn 36, Issue 5, 2003, Pages 411-413

  McIlwain, Laura ^a   Carter, John D ^a,b   Bin Sagheer, Syed ^a   Vasey, Frank B ^a   Nord, Juergen ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Crohn disease; Hypersensitivity vasculitis; Infliximab; Leukocytoclastic vasculitis; Tumor necrosis factor inhibitors

Indexed keywords

DIPHENHYDRAMINE; INFLIXIMAB; METHYLPREDNISOLONE; RANITIDINE;

ADULT; ALLERGIC VASCULITIS; ARTICLE; BIOPSY; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; DISEASE COURSE; DRUG EXPOSURE; FEMALE; HUMAN; LEUKOCYTOCLASTIC VASCULITIS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DRUG HYPERSENSITIVITY; GASTROINTESTINAL AGENTS; HUMANS; MALE; VASCULITIS, HYPERSENSITIVITY;

EID: 0037405058     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200305000-00010     Document Type: Article

References (11)

1. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999:340:1398-405.
2. Van Dullemen HM, Van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
3. Hanauer SB, Cohen RD, Becker RV III, et al. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther 1998;20:1009-28.
4. Garrison L, McDonnell ND. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58(suppl 1):165-9.
5. McCain ME, Quiney RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology 2002;41:116-7.
6. Van Deventer SJH. Anti-TNF antibody treatment of Crohn's disease. Ann Rheum Dis 1999;58(suppl 1):I114-20.
7. Beltrani V. Drug hypersensitivity: cutaneous manifestations of adverse drug reactions. Immunol Allergy Clin North Am 1998;18:867-95.
8. Zlatanic J, Fleisher M, Sasson M, et al. Crohn's disease and acute leukocytoelastic vasculitis. Am J Gastroenterol 1996:91:2410-3.
9. Galaria N, Werth V, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000:27:2041-4.
10. Rutgeerts P, D'Haens G, Van Deventer S, et al. Retreatment with anti-TNF-alpha chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease [abstract]. Gastroenterology 1997;112:A1078.
11. Keane J, Gershon S, Wise RP, et al. M. tuberculosis associated with infliximab, a tumor necrosis factor neutralizing agent. N Engl J Med 2001:345:1098-104.